DTRA awards $9.7M contract for drug development aimed at viral threats
The Defense Threat Reduction Agency (DTRA) has awarded Emory University a $9.7M contract to develop drugs to treat infections caused by emerging and man-made viral threats. Under the contract, the DTRA funds will be used to advance the development of the lead drug candidate.
"This contract demonstrates our abilities to discover and develop drugs for urgent public health needs. Our goal is to help make the world healthier and less dangerous," says Dennis Liotta, PhD, executive director of EIDD. Dr. Liotta is a faculty member in the MSP program.